HIV/AIDS 2010: Better drugs, better technologies, and lingering problems

Archives of Internal Medicine

Volumn 170, Issue 1, 2010, Pages 6-8

  Katz, Mitchell H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; DRUG RESEARCH; EDITORIAL; GASTROINTESTINAL SYMPTOM; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; PRIORITY JOURNAL; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 74549143716     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.442     Document Type: Editorial

References (26)

1. Bhaskaran K, Hamouda O, Sannes M, et al; CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51-59.
2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185-191.
3. Volberding PA, Lagakos SW, Koch MA, et al; The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322(14):941-949.
4. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med. 1993;326:437-443.
5. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine: AIDS in Europe Study Group. JAMA. 1994;271(14):1088-1092.
6. Moore RD, Keruly JC, Chaisson RE. Duration of the survival benefit of zidovudine therapy in HIV infection. Arch Intern Med. 1996;156(10):1073-1077.
7. Palella FJ Jr, Delaney KM, Moorman AC, et al; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860.
8. Elzi L, Marzolini C, Furrer H, et al; the Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57-65.
9. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18(10):1393-1401.
10. McNicholl IR. Strategies to enhance adherence, reduce costs, and improve patient quality of life. J Manag Care Pharm. 2008;14(suppl a):S12-S16.
11. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Med Decis Making. 2008;28(3):359-376.
12. Golin CE, Smith SR, Reif S. Adherence counseling practices of generalist and specialist physicians caring for people living with HIV/AIDS in North Carolina. J Gen Intern Med. 2004;19(1):16-27.
13. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
14. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446-453.
15. Zetola NM, Grijalva CG, Gertler S, et al. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003-June 2007. PLoS One. 2008;3(7):e2591.
16. Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006;8(2):125-131.
17. Patel P, Mackellar D, Simmons P, et al; Centers for Disease Control and Prevention Acute HIV Infection Study Group. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med. 2010;170(1):66-74.
18. Centers for Disease Control and Prevention (CDC). Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep. 2008;57(RR-9):1-83.
19. Estimates of new HIV infection in the United States: CDC HIV/AIDS facts: August 2008. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/incidence.htm. Accessed October 21, 2009.
20. 2008 Report on the global AIDS epidemic: executive summary. UNAIDS Web site. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008- Global-report.asp. Accessed October 21, 2009.
21. Centers for Disease Control and Prevention (CDC). Achievements in public health: reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592-597.
22. Lyles CM, Kay LS, Crepaz N, et al; HIV/AIDS Prevention Research Synthesis Team. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US population at high risk, 2000-2004. Am J Public Health. 2007;97(1):133-143.
23. Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. AIDS Behav. 2008;12(3):335-353.
24. Buchbinder S. The epidemiology of new HIV infections and interventions to limit HIV transmission. Top HIV Med. 2009;17(2):37-43.
25. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10(3):315-336.
26. Stover K. In Thailand clinical study, HIV vaccine regimen demonstrates modest preventive effect. Medical News Today Web site. http://www. medicalnewstoday.com/articles/165277.php. Accessed September 25, 2009.